Research programme: graft versus host disease therapeutics - CAGE Bio/Mayo Clinic
Latest Information Update: 21 Jan 2026
At a glance
- Originator CAGE Bio
- Developer CAGE Bio; Mayo Clinic
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Graft-versus-host disease